mutation: targeted therapies, consisting of BRAFi and MEKi, and immunotherapies. Immunotherapies have displayed long-term effect on a subset of patients but, to date, there are no tools to identify those patients that will benefit from immunotherapies. On the other hand, targeted therapies have immediate effect in term of tumour shrinkage, but the benefit is short-term as resistance occurs after few months in almost every case. As a further matter, some patients do not respond at all to BRAF inhibition because of intrinsic resistance to the treatment. The addition of a MEK inhibitor to the regimen was initially identified as a promising approach to overcome BRAFi-resistance, and hence the combination of BRAFi/MEKi has been approved. [4] [5] [6] However, in numerous cases the BRAFi/MEKi combination just delays the emergence of resistance as observed when we compare the median progression-free survival of patients receiving the monotherapy (7.3 months) vs the combination (14.9 months). 3 More recently, re-challenging non-responding tumour after a drug holiday period has been suggested as an alternative therapeutic strategy in BRAF-mutated melanomas 8, 9 and it has been shown to be beneficial in a subset of patients. [10] [11] [12] [13] [14] [15] However, safe longitudinal biomarkers to identify the patients who may benefit from the intermittent treatment, or to establish the optimal drug holiday duration, are missing.
Several studies have recently helped deciphering the interplay between oncogenic MAPK signalling, melanoma metabolism and BRAFi-resistance. Apart from a small subset of melanomas, BRAF mutations are associated with increased glycolysis and attenuated oxidative phosphorylation, and such balance is reversed upon treatment with BRAFi. [16] [17] [18] [19] [20] Resistance to BRAFi seems to be accompanied by precise metabolic changes as well: higher reliance on oxidative phosphorylation, [21] [22] [23] [24] glutamine dependency 21, 25, 26 and up-regulated serine metabolism. 26, 27 Besides suggesting novel targetable metabolic vulnerabilities, the fast-increasing knowledge in tumour metabolism will hopefully help identifying candidate biomarkers of clinical utility. To date, the lack of validated markers exploiting the aforementioned metabolic alterations to discriminate responding and non-responding melanomas in patients still hinders the long-term effectiveness of current treatment options and represents a barrier to the advancement of personalized medicine.
Metabolic markers such as 13 C magnetic resonance spectroscopy of hyperpolarized substrate may bridge this gap, as they allow to assess crucial metabolic fluxes whose alteration is indicative of treatment response or tumour progression. Notably, hyperpolarization of 13 C-enriched metabolites increases 13 C magnetic resonance spectroscopy (MR) sensitivity by a factor of 10 000, allowing in vivo real-time assessment of metabolic fluxes. In particular, [1-13 C] pyruvate is reduced to [1-13 C] lactate via the enzyme lactate dehydrogenase (LDH). This process results in an altered chemical shift that HP MRI can image at uniquely high-temporal resolution. Hyperpolarized [1-13 C] pyruvate has been safely administered in patients, and its conversion into [1-13 C] lactate was higher in prostate tumours compared with healthy tissue, which was in agreement with previous preclinical studies. 28 The use of hyperpolarized [1-13 C] pyruvate for metabolic imaging of prostate, breast, brain and cervical cancer and other diseases is currently being evaluated in several clinical trials. 29 In addition to pyruvate, several other 13 C enriched substrates have been hyperpolarized, with their conversion being successfully observed in vivo. 29 The aim of this study is to evaluate whether magnetic resonance spectroscopy of hyperpolarized [1-13 C] pyruvate can discriminate between responding and resistant BRAF V600E melanoma cells and xenografts, by exploiting the effect of BRAFi on tumour metabolism.
| ME THODS

| Cell culture
Sensitive (A375) and resistant (A375R) melanoma cells were treated for 24 hours with 2 µmol/L of the BRAFi vemurafenib or DMSO. The resistant cell line was generated via exposure to increasing concentration of the drug. 30 Cells were cultured at 37°C in a humidified atmosphere with 5% CO 2 and maintained in Dulbecco's modified Eagle's medium (DMEM, Thermo Fisher Scientific) supplemented with 10% heat-inactivated FBS (Thermo Fisher Scientific).
| Animal studies
Experiments involving animals were undertaken in accordance with the Belgian law concerning the protection and welfare of the animals and were approved by the UCLouvain ethical committee (agreement reference: UCL/2014/MD/026). All investigators performing in vivo studies successfully completed FELASA C training.
| Tumour xenografts
2 × 10 6 A375 cells in 100 μL of PBS were subcutaneously injected in the right hind paw of 6-week-old female nude NMRI mice (Janvier).
During inoculation, mice were kept under inhalational anaesthesia with 2.5% isoflurane in 2 L/min airflow. Mice were treated with daily intraperitoneal injection of vemurafenib (50 mg/kg, Active Biochem) or vehicle (DMSO, Sigma-Aldrich).
| Hyperpolarized 13 C-MRS
For hyperpolarization experiments, 10 or 40 µL of [1- 13 Following HP experiments, melanoma xenografts were collected and processed for further analysis (immunohistochemistry, WB, qRT-PCR). 
| 13 C-MRS
| In vitro EPR spectroscopy
The effect of BRAFi on the oxygen consumption rate was evaluated on A375 and A375R cells via an X-band EPR spectrometer operating at 9 GHz (Bruker EMXplus). Cells were incubated with 2 µmol/L of BRAFi for 24 hours; after trypsinization, cells were resuspended in cell growth medium at a concentration of 9 × 10 6 cells/mL and 100 µL of cell suspension was mixed with 100 µL of 20% w/v of dextran in 0.9% NaCl solution and 8 µL of 0.2 mmol/L 15 N-PDT, which served as oxygen sensor. A 75 µL-glass capillary tube (Hirschmann Labogeräte) was filled with the cell suspension, sealed and inserted into a quartz tube, then placed into the EPR cavity. The cavity was continuously flushed with a gas mixture (400 L/h) at 37°C throughout the spectra acquisition. EPR spectra were acquired every 60 seconds, and pO 2 values were obtained by measuring the peak-to-peak EPR signal linewidths, which was then converted into pO 2 by means of a calibration curve. Oxygen consumption rate (OCR) was then calculated as the slope of pO 2 over time curve.
| In vivo EPR spectroscopy
For in vivo EPR experiments, when the shortest tumour diameter reached 5 mm, 50 µL of charcoal suspension (100 mg/mL in 0.9% NaCl containing 3% Arabic gum) was injected intratumorally.
The day after charcoal injection, mice were randomized into two groups (BRAFi-treated or control) and longitudinal EPR measurements were started. Spectra were acquired on a 1.15-GHz EPR spectrometer (ClinEPR). Typical acquisition parameters were as follows: modulation of amplitude 0.4 G, modulation of frequency 21 kHz. During EPR experiments, animals were kept under inhalational anaesthesia with isoflurane (2.5% during anaesthesia induction and 1.2% during maintenance) in 2 L/min airflow. Acquisition was started 5 minutes after setting isoflurane to 1.2%. Tumour pO 2 values were obtained by measuring the peak-to-peak EPR signal linewidth, which was then converted into pO 2 by means of a calibration curve.
| qRT-PCR
Total RNA was extracted from cells and tumour tissue powder Data were analysed using the 2 −ΔΔCT method. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as housekeeping gene. Primers for GLUT1, HK2, MCT1, MCT4, LDHA, ALT2, PDK1, MPC1 and c-MYC are listed in Appendix S1.
| Western blot
Adherent A375 and A375R cells were lysed in RIPA buffer (Thermo Scientific) supplemented with 1% protease and phosphatase inhibi- 
| Immunohistochemistry
Melanoma xenografts were fixed in 4% formaldehyde and embedded in paraffin. After rehydration, 5 µm sections were submitted to antigen retrieval using citrate buffer. Sections were then incubated in BSA 5% in TBS/Triton 0,05% to block non-specific binding, then overnight at 4°C with primary antibodies for CD31 (Cell Signaling Technology). Envision anti-rabbit secondary polymer antibody was used (Dako). Stained slides were then digitalized using a SCN400 slide scanner (Leica Biosystems) at 20× magnification and analysed using TissueIA software (Leica Biosystems). The quantification algorithm was run in the non-necrotic part of the tissues. 
| Statistical analysis
| RE SULTS
| Hyperpolarized 13 C MRS detects metabolic changes induced by BRAFi in vivo
Following intravenous injection of hyperpolarized (HP) [ Figure 1A ). 13 C signal arising from alanine was only observed in four mice (33%).
The 13 C label exchange between HP pyruvate and lactate increased 24 hours after treatment with vemurafenib (P = .3839 in controls and P = .0171 in BRAFi-treated mice) ( Figure 1B ). This effect occurred before any significant change in tumour volume. The tumour size of control melanoma xenografts became significantly larger 3 days after the start of the experiment (P = .3892 at day 1, P < .0001 at day 3 and 5), whereas the growth of treated melanoma xenografts was initially stabilized by the treatment, and significant tumour shrinkage occurred after 5 days (P = .4395 at day 1, P = .0567 at day 3 and P = .0005 at day 5) ( Figure 1C) . To explain the increase in the HP lactate/pyruvate ratio, we have measured protein and mRNA levels of key glycolytic enzymes and transporters in tumour xenografts collected right after the hyperpolarization experiments. Of note, the HP pyruvate-to-lactate conversion was increased in all but one animals after treatment, compared with baseline, but the two groups did not significantly differ at 24 hours (P = .3078 in controls versus treated mice at baseline and P = .2050 at 24 hours). This highlights the importance of longitudinal, individual monitoring compared with the measurement of averages in groups. This approach, however, is not always feasible when quantifying proteins or mRNA levels in tissues.
Therefore, for the ex vivo analysis, we have compared the two groups at 24 hours after treatment with BRAFi or vehicle.
In treated xenografts, the glucose transporter GLUT1 was significantly lower both at the mRNA (P = .0010) and protein (P = .0440) level, when compared to control xenografts (Figure 2A-C) . Treated xenografts also showed lower mRNA levels of HK2, PDK1 (P = .0037
and P = .0046, respectively) and a significant reduction in c-MYC protein levels (P = .0018) (Figure 2A -C).
| BRAFi impairs glycolysis and oxygen consumption in BRAFi-sensitive, but not in BRAFiresistant, melanoma cells
BRAF inhibition resulted in a decrease of 13 C label exchange between HP pyruvate and lactate in A375 in vitro, but not in A375R cells (P = .0075 and P = .8898, respectively) ( Figure 3A,B ). 13 C signal arising from alanine was observed in all but one sample. The label distribution between alanine and lactate was also significantly modified by BRAFi in A375, but not in A375R cells (P = .0333 and P = .8397) ( Figure S1A ).
Next, we measured the intracellular and extracellular water-soluble metabolites in melanoma cells incubated with [U-13 C] glucose.
We observed a reduction in extracellular lactate in both sensitive and resistant melanoma cells treated with BRAFi, when compared to their untreated counterpart (P = .0002 and P < .0001, respectively).
Extracellular glucose was significantly higher in BRAFi-treated A375 cells (P < .0001), thus suggesting that treatment affected glucose uptake, as later confirmed via qRT-PCR and Western blot analysis of GLUT1 ( Figure 3C ).
In regard to the intracellular metabolites, lactate pool was decreased both in A375 and A375R cells upon inhibition of BRAF (P < .0001 for both A375 and A375R compared with their own controls). Resistant A375R cells; however, had a significantly higher amount of intracellular lactate at baseline (P < .0001) ( Figure 3C ).
The glycolytic efficiency, calculated as the ratio of extracellular lactate over consumed glucose, decreased following BRAFi in sensitive A375 cells (P = .0062), but not in A375R cells (P = .4765) ( Figure 3D ). In sensitive cells, the intracellular alanine/lactate ratio was significantly modified after treatment as well (P = .0146 for A375 and P = .4765 for A375R) ( Figure S1B ).
The decrease in glycolysis was accompanied by an increase in the oxygen consumption rate in sensitive cells treated with the BRAFi, as demonstrated by in vitro EPR spectroscopy ( Figure 3E ).
| BRAFi affects the transcription of key glycolytic enzymes and transporters in sensitive melanoma cells
Our qRT-PCR data showed a significant decrease in the mRNA levels of HK2, c-MYC and MCT1 in BRAFi-treated A375 cells, compared with untreated controls (P = .0046, P = .0279 and P = .0076, respectively), but neither of them was affected by the treatment in resistant A375R cells. ALT2 and MPC1 mRNA levels were not modified by treatment neither in A375 nor in A375R cells. However, ALT2 levels were higher at baseline in resistant cells (P = .0490) ( Figure 4A ). 
| BRAFi reduces hypoxia in vivo, as assessed by electron paramagnetic resonance (EPR) oximetry
Our in vitro results confirmed that BRAFi reduced the glycolytic activity of sensitive melanoma cells, thus resulting in a decrease 13 to understand whether the increased label exchange observed in vivo was due to treatment-induced hypoxia.
EPR oximetry indicated that melanoma xenografts were highly hypoxic (pO 2 < 1.5 mm Hg). BRAFi led to an increase in the oxygen partial pressure (pO 2 ) of treated tumours, as measured by the peakto-peak signal linewidth of the oxygen sensor ( Figure 5A ). Such effect occurred after 3 days of treatment, and it was still present after 5 days of treatment (P = .0002 at day 3 and at day 5) ( Figure 5B ).
Immunohistochemical analysis of tumour xenografts collected at baseline and after 1 or 5 days of treatment did not show any significant variation in the angiogenesis marker CD31 (Figure 5D,E) . These results suggest that the increased pO 2 observed via in vivo EPR experiments may be due to a reduced oxygen consumption in vivo, contrarily to what was observed in vitro. A reduction in the cell density caused by
BRAFi could have caused a decrease in oxygen demand and hence, an increase in tumour pO 2 . Another possible explanation is that BRAFi has improved oxygenation without affecting blood vessel density.
| D ISCUSS I ON
Inhibition of BRAF led to a significant increase in the HP pyruvateto-lactate label exchange as soon as 24 hours after treatment administration, before any significant tumour shrinkage.
This effect was paradoxical, as BRAFi is known to inhibit glycolysis in BRAF-mutated melanomas. 17, 18, 33, 34 Accordingly, our ex vivo analysis of sensitive melanoma xenografts showed significantly lower mRNA levels of GLUT1, HK2 and PDK1 in the treated group, as well as lower C-MYC and GLUT1 protein levels. Of note, we did not observe any significant effect of BRAFi on LDHA and MCT1/4, the most important factors that influence the 13 C label exchange between hyperpolarized pyruvate and lactate. 17, [35] [36] [37] To explain the paradoxical increase in HP pyruvate-to-lactate conversion observed in vivo, we assessed hyperpolarized pyruvate in melanoma cells in vitro, thereby excluding the contribution of tumour microenvironment. Contrarily to what was observed in vivo,
BRAFi induced a decrease in HP pyruvate-to-lactate conversion by sensitive melanoma cells. The impairment of glycolysis was accompanied by an increase in oxygen consumption rate, consistent with
BRAFi-mediated stimulation of mitochondrial metabolism. 16 Our in vitro hyperpolarization results confirm and extend the work of Beloueche-Babari and colleagues: they observed a BRAFi-mediated drop in the HP pyruvate-to-lactate exchange in the BRAF-mutated cell line WM266.4, but not in cells harbouring wild-type BRAF, therefore, intrinsically resistant to BRAFi. 17 By using a BRAFiresistant clone derived from the parental cell line, 30 we have shown that the effect in term of reduced glycolysis and label exchange is specific to sensitive cells and may not be present in BRAF-mutated F I G U R E 5 BRAFi reduced hypoxia in vivo, without affecting the vessel density. A, Representative EPR spectra obtained from a mouse prior treatment (top) and after 5 d of treatment with vemurafenib (bottom). Capped lines identify the peak-to-peak EPR signal linewidth B, Longitudinal measurements of pO 2 in control (in blue) and daily BRAFi-treated (in red) mice (two-way ANOVA, Sidak multiple comparisons test, ***P < .001) (n = 7). C, Vascular density measured as the ratio of the CD31 positive area/ total tissue area, in melanoma xenografts collected at baseline or after 1 d or 5 d of treatment with BRAFi (n = 3-6) or DMSO (n = 4-6). D, Representative CD31 staining of melanoma xenografts after 1 or 5 d of treatment. Scale bar: 100 µm cells with acquired resistance due to previous exposure to the drug.
In line with a reduction of glycolytic activity, following BRAFi in vitro we observed a reduction in mRNA and protein levels of glycolytic enzymes, as well as a decrease in cell glycolytic efficiency, as measured by steady-state levels of polar metabolites.
We next asked whether the increase pyruvate-to-lactate conversion observed in vivo originated from hypoxia. Therefore, we performed immunohistochemical analysis of CD31 and in vivo EPR oximetry, to evaluate changes in tumour vasculature and pO 2 , respectively. We did not observe any significant change in tumour vasculature, nor in tumour pO 2 24 hours after treatment, thereby suggesting that the increased pyruvate-to-lactate 13 Within the scope, immunocompetent mice would allow to obtain a more thorough picture of the cross-talk between cancer cells and immune cells. This is all the more important in immunogenic tumours such as melanoma.
Our study points out some aspects that may be taken into account in future research.
The opposite effect of BRAFi in melanoma cells versus xenografts herein observed corroborates recent literature highlighting the importance of animal studies, with the twofold objective of better understanding the links between oncogenic signals and metabolism, while taking into account tumour heterogeneity, and fostering the clinical translation of newly developed hyperpolarized probes. 29, 41 Finally, discrepancies between the tumour metabolism of HP probes and steady-state levels of the same metabolites are possible. In fact, contrarily to what happens in physiological conditions,
in hyperpolarization experiments the cell metabolism is challenged via the injection of a supra-physiological dose of the hyperpolarized probe. 46 The conversion of a hyperpolarization probe and the measurements of steady-state metabolite levels therefore provide different and complementary information. In our in vitro study, the two approaches provided strikingly similar results, thus suggesting that in this particular model the label exchange between hyperpolarized pyruvate and lactate faithfully described the physiological pyruvate-to-lactate conversion.
| CON CLUS ION
Following BRAFi, the HP pyruvate-to-lactate conversion was significantly increased in human melanoma xenografts. This effect preceded both changes in tumour volume and in tumour oxygenation, thus indicating that the HP lactate/pyruvate ratio may serve as an early marker of response to BRAFi in melanoma. Contrarily to the in vivo settings, BRAFi significantly decreased the HP lactate/pyruvate ratio in vitro, suggesting that such conversion is highly influenced by tumour microenvironment. Future studies are needed to elucidate the precise contribution of stromal cells on the metabolism of HP pyruvate in vivo.
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